A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 912
- Population
- ALL
- Duration
- 2015-01-09 to 2019-07-08
- Intervention
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Comparator
- Not reported
- Outcomes measured
- Mean change of visual acuity from baseline to 12 months. — Baseline to 12 months; Mean change of visual acuity from baseline to 24 months. — Baseline to 24 months; Number of clinical visits (visits for injections) — At 12 and 24 months; Number of monitoring visits (visits only for diagnostic purposes, but without injections) — At 12 and 24 months; Number of combined visits (visits for monitoring and injection) — At 12 and 24 months; Number of post-injection monitoring visits (visits only for safety checks after injection) — At 12 and 24 months; Number of visits outside the study center after 12 and 24 months — At 12 and 24 months; Number of optical coherence tomography (OCT) assessments per patient — At 12 and 24 months; Number of visual acuity tests — At 12 and 24 months; Number of fundoscopy examinations — At 12 and 24 months; Mean time between the injections and visits — At 12 and 24 months; Mean time between the first symptoms and diagnosis — Up to 24 months; Mean time from indication of the Eylea treatment by the treating physician to treatment — Up to 24 months; Proportion of patients with no fluid — At 4,12 and 24 months; Mean change in retinal thickness from baseline — Baseline and at 4,12 and 24 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.